FDA expands use of Opdivo to include urothelial carcinoma

Organisation: Position: Deadline Date: Location:

The US Food and Drug Administration has expanded the use of Bristol-Myers Squibb Co’s Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer, reports Reuters Health.

Opdivo, part of a new class of medicines designed to use the body’s own immune system to fight cancer, is already approved to treat advanced melanoma, a form of lung cancer, kidney cancer, and Hodgkin lymphoma.

The report says the FDA is slated to decide in May whether to approve rival Merck & Co Inc’s combination of immunotherapy Keytruda and chemotherapy for first-line lung cancer.

Reuters Health report
FDA material


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.